Johnson & Johnson

JNJ Healthcare Drug Manufacturers - General NYSE

PDF Back to Search

$201.93

$-0.55 (-0.27%)

Open: $202.98 | High: $203.45 | Low: $200.81 | Prev Close: $202.48

Market Cap: $486.51B

Volume: 6.9M | Avg: 8.7M

Last updated: December 05, 2025 at 10:04 PM
Investment Rating
A-

Buy

Overall Score: 80/100

Rating Breakdown:
DCF Score 4/5
80%
Buy
ROE Score 5/5
100%
Strong Buy
ROA Score 5/5
100%
Strong Buy
D/E Score 3/5
60%
Neutral
P/E Score 2/5
40%
Sell
P/B Score 2/5
40%
Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 555

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 45
Financial Health 75
Growth 20
Market Sentiment 20
Risk 50
Lower is better
Valuation 30
Momentum 15
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 19.51
P/B Ratio 6.19
P/S Ratio 5.28
EPS $10.35
Beta 0.36
Shares Outstanding 2.41B
Price Range & Moving Averages
52-Week High $207.81
52-Week Low $140.68
SMA 50 $193.01
SMA 200 $170.06
Dividend Information
Dividend Yield 2.55%
Annual Dividend $5.14
Earnings
Next Earnings January 21, 2026 01:30 PM ET
Financial Ratios
Margins
Gross Margin 68.1%
Operating Margin 26.1%
Net Margin 27.3%
Returns
ROE 32.7%
ROA 13.0%
Liquidity & Leverage
Debt/Equity 0.08
Current Ratio 1.07
Quick Ratio 0.80
Balance Sheet
Total Assets $180.10B
Total Liabilities $108.61B
Total Equity $71.49B
Cash $24.11B
Total Debt $37.83B
Net Debt $13.73B
Income Statement
Revenue $88.82B
Gross Profit $61.35B
Operating Income $22.15B
Net Income $14.07B
EBITDA $24.78B
Revenue/Share $37.94
Cash Flow
Operating CF $24.27B
CapEx $4.42B
Free Cash Flow $19.84B
Book Value/Share $32.64
Tangible Book/Share $-7.21
Equity/Share $32.64
Technical Indicators
RSI (14) 70.60 Overbought
MACD
4.21 Signal: 4.33
Volatility 15.27%
Trading Signal Overbought
Performance & Returns
Total Returns
1 Year +27.89%
Risk-Adjusted Returns
Sharpe Ratio 1.41 Good
Volatility (Ann.) 19.5% Low Risk
vs S&P 500 (SPY)
JNJ (1Y) +27.89%
S&P 500 (1Y) +11.86%
Alpha (Excess Return) +16.03%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 59 peers in Healthcare
Metric JNJ Sector Avg Percentile
P/E Ratio 19.51 31.4 37%
P/B Ratio 6.19 -0.66 75%
ROE (%) 32.69% 9.41% 82%
Net Margin (%) 27.26% 9.76% 83%
Stock Score 555 503.0 73%
1Y Return (%) +27.89% +4.02% 85%
Percentile: 0% = worst in sector, 100% = best in sector
Historical Price Analysis (Last 200 Days)
Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
JNJ $201.93 $205.10 $205.72 $204.22 $193.01 $170.06 70.60 4.21 15.27% 9049943 Weak Short Price Below SMAs
Candlestick Patterns

There wasn't any recognizable pattern for the JNJ stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
JNJ Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note Neutral zacks.com Read More
JNJ The Dividend Stocks That Keep Paying Even When Markets Stumble Neutral 247wallst.com Read More
JNJ 3 Large Drug Stocks to Watch as the Industry Shows Some Recovery Neutral zacks.com Read More
JNJ Edgestream Partners L.P. Sells 63,615 Shares of Johnson & Johnson $JNJ Neutral defenseworld.net Read More
JNJ Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Neutral seekingalpha.com Read More
Company Information

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

CEO Joaquin Duato
Employees 138100
Country US
IPO Date 1943-01-02
Exchange NYSE
Website https://www.jnj.com
Sector Healthcare
Industry Drug Manufacturers - General
Similar Stocks (Healthcare - Drug Manufacturers - General)
LLY

Eli Lilly and Company

Price: $1010.31
Change: -0.41%
Market Cap: $9075B
P/E: 49.55
Score: D (580)
View Details
ABBV

AbbVie Inc.

Price: $226.08
Change: -1.15%
Market Cap: $3995B
P/E: 172.58
Score: E (405)
View Details
MRK

Merck & Co., Inc.

Price: $99.72
Change: -1.16%
Market Cap: $2506B
P/E: 13.19
Score: D (580)
View Details
AMGN

Amgen Inc.

Price: $329.89
Change: -3.02%
Market Cap: $1776B
P/E: 25.51
Score: E (465)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.